|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500112275 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-12 10:23:06 |
|
注册时间: Date of Registration: |
2025-11-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
脑卒中患者认知能力康复改善评估及预测的生物标志物研究 |
|
Public title: |
Biomarker-Based Study for the Assessment and Prediction of Cognitive Recovery in Patients with Stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑卒中患者认知能力康复改善评估及预测的生物标志物研究 |
|
Scientific title: |
Biomarker-Based Study for the Assessment and Prediction of Cognitive Recovery in Patients with Stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
幸雯 |
研究负责人: |
幸雯 |
|
Applicant: |
Xing Wen |
Study leader: |
Wen Xing |
|
申请注册联系人电话: Applicant telephone: |
+86 10 87569183 |
研究负责人电话: Study leader's telephone: |
+86 10 8756 9187 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xingwenpumc@126.com |
研究负责人电子邮件: Study leader's E-mail: |
xingwenpumc@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国康复研究中心北京博爱医院 |
研究负责人通讯地址: |
北京市丰台区角门北路10号 |
|
Applicant address: |
Beijing Bo'ai Hospital, China Rehabilitation Research Center |
Study leader's address: |
No. 10, Jiaomen North Road, Fengtai District |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国康复研究中心北京博爱医院检验科 |
||
|
Applicant's institution: |
Department of Clinical Laboratory, Beijing Bo'ai Hospital, China Rehabilitation Research Center |
||
|
研究负责人所在单位: |
北京博爱医院 |
||
|
Affiliation of the Leader: |
Beijing Bo'ai Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-092-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国康复研究中心医学伦理委员会科研与医疗新技术新项目伦理组 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of China Rehabilitation Research Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-12 00:00:00 |
||
|
伦理委员会联系人: |
何照楠 |
||
|
Contact Name of the ethic committee: |
He Zhaonan |
||
|
伦理委员会联系地址: |
北京市丰台区角门北路10号 |
||
|
Contact Address of the ethic committee: |
No. 10, Jiaomen North Road, Fengtai District |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8702 0512 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
hznhzk@163.com |
|
研究实施负责(组长)单位: |
北京博爱医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Bo'ai Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区角门北路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 10, Jiaomen North Road, Fengtai District |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded research project |
||||||||||||||||||||||
|
Target disease: |
Post-stroke cognitive impairment, PSCI |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
比较健康对照、卒中后无认知障碍组、认知显著改善组、认知无显著改善组四组间BDNF、P-Tau181、NfL、PGP9.5的基线差异;分析指标与康复治疗前/后认知功能的相关性;评价血液学指标对康复治疗后、长期(6/12个月)的认知能力的预测价值;联合神经特异性标志物、常规检验指标、临床信息,预测康复治疗后、长期的认知能力的改善恢复情况。 |
||||||||||||||||||||||
|
Objectives of Study: |
Compare baseline differences in BDNF, P-Tau181, NfL, and PGP9.5 among the healthy control group, post-stroke without cognitive impairment group, significant cognitive improvement group, and non-significant cognitive improvement group; Analyze the correlation between these biomarkers and cognitive function before/after rehabilitation; Evaluate the predictive value of hematological indicators for long-term (6-/12-month) cognitive ability post-rehabilitation; Integrate neuron-specific biomarkers, routine laboratory indices, and clinical information to predict improvement and recovery of long-term cognitive ability following rehabilitation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
卒中组:; 1.患者经 MRI /CT证实为急性脑卒中(影像学资料完整),入院时为卒中发病4~6周; 2.均为右利手; 健康对照组:; 1.与卒中组年龄、性别相匹配的健康体检者;完成MMSE评估,且MMSE评分≥27分; 2.均为右利手; |
||||||||||||||||||||||
|
Inclusion criteria |
Stroke Group:; 1. Patients with acute stroke, medically confirmed by MRI/CT (complete imaging data available), admitted to the hospital at 4-6 weeks post-stroke onset; 2. All participants are right-handed; Healthy Control Group:; 1. Age- and gender-matched healthy volunteers, Completed Mini-Mental State Examination (MMSE) assessment, with an MMSE score >= 27 (adjusted for educational level where applicable); 2.All participants are right-handed; |
||||||||||||||||||||||
|
排除标准: |
卒中组:; 1.失语、严重听力或视力障碍; 2.发病前已存在意识水平下降,或因感染/代谢性疾病,神经变性疾病等引起的认知障碍的患者(如阿尔茨海默病、抑郁症等); 3.脑卒中后病情严重,伴有意识障碍无法配合检查者; 4.患有心脏、肺、肝等脏器功能异常或内分泌系统疾病,或结缔组织疾病,血液疾病; 5.有精神疾病或行为障碍史。 健康对照组:; 1.有神经、精神系统疾病史; 2.有显著影响认知系统的疾病(甲状腺功能异常且未稳定治疗、严重糖尿病等); 3.有严重的心血管系统、呼吸系统疾病,或肝肾功能异常、恶性肿瘤等; 4.妊娠或哺乳期。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Stroke Group: 1. Patients with aphasia , severe hearing or visual impairment; 2. Patients with pre-stroke decreased level of consciousness , or pre-existing cognitive impairment due to conditions such as infection, metabolic disorders, or neurodegenerative diseases (e.g., Alzheimer's disease, depression, etc.); 3. Patients severely ill post-stroke with impaired consciousness preventing cooperation with examinations; 4. Patients with dysfunction of major organs (e.g., heart, lung, liver), endocrine disorders, connective tissue diseases, or hematologic diseases; 5. Patients with a history of psychiatric illness or behavioral disorders . Healthy Control Group: 1. Individuals with a history of neurological or psychiatric disorders; 2.Individuals with diseases significantly affecting the cognitive system (e.g., unstable thyroid dysfunction without stabilized treatment , severe diabetes mellitus, etc.); 3.Having severe cardiovascular or respiratory diseases, or liver and kidney dysfunction, malignant tumors, etc; 4. Individuals who are pregnant or lactating. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-30 00:00:00至 To 2028-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-12-01 00:00:00 至 To 2028-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
学术论文发表后,经研究者同意后可邮箱获取; |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After academic papers are published, they can be obtained via email with the researcher's consent. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
从病历记录表及电子病历系统采集获得的数据,以电子版形式保存。所有研究数据(包括患者个人信息、临床资料、实验室结果等)将严格保密,仅限研究团队成员在授权范围内使用。 电子数据储存于医院加密服务器或密码保护的专用计算机,纸质资料保存于上锁的文件柜,确保未经授权人员无法触及。 患者姓名、身份证号等敏感信息将匿名编码(如病例编号)代替,研究报告中不出现可识别身份的任何信息。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collected from medical record forms and the electronic health record (EHR) system will be preserved in electronic format. All research data—including patients' personal information, clinical records, laboratory results, and other relevant materials—will be kept strictly confidential. Access is restricted exclusively to authorized research team members within approved scope of use. Electronic data will be stored on hospital-encrypted servers or password-protected dedicated computers, while physical documents will be secured in locked filing cabinets, ensuring they remain inaccessible to unauthorized personnel. Sensitive identifiers such as patient names and ID numbers will be replaced with de-identified coding (e.g., case numbers). No personally identifiable information will appear in any research reports or publications. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |